Indirect enzyme-linked immunosorbent assay for the quantitative estimation of lysergic acid diethylamide in urine
Clinical Chemistry May 1, 1998 Sarah Kerrigan, Donald E Brooks 6 citations
A new antibody targeting LSD enabled the development of an indirect ELISA that measures LSD in urine with better performance than a commercial assay. The test uses 50 μL of urine and detects concentrations from ng/L to μg/L. The limit of detection is 8 ng/L, compared to 85 ng/L for the commercial assay, and analytical recoveries range from 98–106%. At 0.1 μg/L, the intraassay coefficient of variation (CV) was 2.4% (n=8), versus 6.0% at 0.5 μg/L for the commercial assay (n=20). The upper and lower quantification limits are 7 μg/L and 50 ng/L. Cross-reactivity with 24 related substances was evaluated. The new assay offers improved sensitivity and precision, enabling more certain quantitative estimation of LSD in urine at lower concentrations.